Biovica, a company active in cancer diagnostics, announced on Friday that it has named Henrik Winther as SVP Business Development and as part of the management team.
Winther most recently held the role of SVP Precision Diagnostics at Immunovia. He has earlier worked as global VP of Business Development at the Danish diagnostics company Dako and later as general manager of the Companion Diagnostic Division at Agilent Technologies based in California. Earlier in his career, Winther headed the R&D diagnostic reagents development at Dako. Prior to that he was associate professor in anatomy, physiology and cell biology at the University of Copenhagen.
Winther, said, 'For a decade, Companion Diagnostics i.e. patient stratification for the right individualised treatment, has been the focus of the industry. Now, the next very important topic to secure safe and effective treatments within personalised cancer medicine is the monitoring of patient response to therapy. Biovica is in a strong position with its DiviTum test which provides a unique tool to oncologists that allows for a fast, robust and reliable assessment of patients' response to a given treatment. DiviTum really has a great potential as it is already CE marked, has interesting applications, support from key opinion leaders globally and several excellent clinical study results. The pieces are in place to take Biovica to the next level.'
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886